Biogen (BIIB) exec says they expect 2026 sales for MS products, excluding Vumerity to decline by the mid teen percentages

Biogen’s executive guidance projecting a mid-teen percentage decline in sales for MS products (excluding Vumerity) by 2026 is a concerning signal for the company.

Newsquawk StaffPublished On the live feed at 8 more headlines followed before this page went public
Newsquawk headlinesUTC

China and South Africa sign a framework agreement on jointly developing an economic partnership, according to the Chinese Commerce Minister

Carlyle Group (CG) executive says software represents 6% of total AUM

Biogen (BIIB) exec says they expect 2026 sales for MS products, excluding Vumerity to decline by the mid teen percentages

EU Commission President von der Leyen says the EU is putting forward a new package of sanctions on Russia covering energy, financial services and trade

US Used Car Prices YoY (Jan) Y/Y 2.4% (Prev. 0.4%)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This likely suggests challenges in maintaining market share or pricing power, which could weigh heavily on investor sentiment and future earnings expectations. Consequently, the forecast may also prompt downward revisions to consensus estimates, influencing valuation and positioning within the biotechnology sector.

Related headlines

The whole workspace, free to try.

Try it free